For example, the dual PI3 K/mTOR inhibitor dactolisib (BEZ235) with panobinostat, as well as the EGFR inhibitor AG1478 alongside sodium butyrate, have both been shown to reduce GBM cell viability and proliferation [269, 270]. Here, EGFR is linked to glioblastoma.